Analyses: Gocovri Works Better to Lessen Off Episodes, Dyskinesia

Analyses: Gocovri Works Better to Lessen Off Episodes, Dyskinesia

306609

Analyses: Gocovri Works Better to Lessen Off Episodes, Dyskinesia

Several new clinical trial data analyses support the benefits and superiority of Gocovri (amantadine) over other therapies in lessening off episodes — periods when levodopa treatments stop working and motor symptoms return — and involuntary movements called dyskinesia in people with Parkinson’s disease. These analyses compared Gocovri, marketed by Adamas Pharmaceuticals, to other levodopa add-on therapies and amantadine-formulations for Parkinson’s. The findings are being presented in five posters at the International Parkinson and Movement Disorder Society…

You must be logged in to read/download the full post.